February 7, 2025 Product Launch

New England Journal of Medicine publishes new data for Roche’s Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis

Nearly half of patients on Gazyva/Gazyvaro plus standard therapy achieved a complete renal response (CRR), with a statistically significant and clinically meaningful improvement, compared to standard treatment alone1 Analysis showed consistent CRR benefit across patient subgroups, highlighting potential to treat a broad patient population with high unmet need1 Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody... Read more

February 4, 2025 Acad, Gov/Utilities

FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness

Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME) With as few as two treatments per year, Susvimo may help people with DME maintain their vision Approval marks the second indication for Susvimo in addition to neovascular or ‘wet’ age-related macular... Read more

February 4, 2025 Environ, Ag./Food & Bev Lab Top-10 M&A, Partnerships PAI Top-10 Product Launch

Thermo Fisher Scientific Accelerates 100 Percent Renewable Electricity Goal for European Operations with New Solar Power Agreement with X-ELIO

Company leads value chain partners in purchase agreement that adds 118 megawatts (MW) of solar energy to enable decarbonization across the pharmaceutical and healthcare industries WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a 10-year virtual power purchasing agreement (VPPA) with international renewable energy developer X-ELIO... Read more

February 3, 2025 Lab Top-10 Other Lab Products/Services PR/Corporate

PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service

MENLO PARK, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggiero as the company’s new Global Head of Sales & Service. Mr. Ruggiero brings over two decades of experience in sales leadership within the technology and life sciences... Read more

January 31, 2025 Acad, Gov/Utilities Bio/Pharma/CRO Clinical Research/Diagn. PAI Top-10 PR/Corporate

Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU

As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered HER2-ultralow.1 These patients may now be eligible for a targeted treatment, which could significantly improve their outcomes. The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since... Read more

January 30, 2025 PR/Corporate

PacBio Announces Appointment of Chris Smith to Board of Directors

MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Chris Smith to its Board of Directors, effective today. Mr. Smith is currently the Chief Executive Officer of NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company. Mr. Smith, a seasoned executive... Read more

January 30, 2025 Environ, Ag./Food & Bev Lab Top-10 PAI Top-10 PR/Corporate

Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2024 Results

WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter and Full Year 2024 Highlights Fourth quarter revenue grew 5% to $11.40 billion. Fourth quarter GAAP diluted earnings per share (EPS) grew... Read more

January 30, 2025 Liq. Handling & Robotics PAI Top-10 PR/Corporate

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth

Basel, 30 January 2025 Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics. Excluding COVID-19, Group sales increased by 9%. COVID-19 will not adversely impact our results from 2025 onwards. The fourth quarter was the third consecutive quarter of 9% sales growth,... Read more

January 29, 2025 Uncategorized

PacBio Technology Powers Landmark Multiomic Study Published in Nature Genetics

MENLO PARK, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leader in high-quality, long-read sequencing, is proud to announce its critical role in a study to be published in Nature Genetics. The study, titled Synchronized long-read genome, methylome, epigenome, and transcriptome for resolving a Mendelian condition, showcases how researchers leveraged PacBio’s advanced sequencing... Read more